Advertisement
Singapore markets close in 2 hours 34 minutes

  • Straits Times Index

    3,290.77
    +24.82 (+0.76%)
     

  • Nikkei

    38,229.11
    +155.13 (+0.41%)
     

  • Hang Seng

    18,917.16
    +379.35 (+2.05%)
     

  • FTSE 100

    8,381.35
    +27.30 (+0.33%)
     

  • Bitcoin USD

    62,872.36
    +1,197.03 (+1.94%)
     

  • CMC Crypto 200

    1,351.71
    -6.30 (-0.46%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • Dow

    39,387.76
    +331.36 (+0.85%)
     

  • Nasdaq

    16,346.26
    +43.46 (+0.27%)
     

  • Gold

    2,367.50
    +27.20 (+1.16%)
     

  • Crude Oil

    79.90
    +0.64 (+0.81%)
     

  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     

  • FTSE Bursa Malaysia

    1,600.58
    -0.64 (-0.04%)
     

  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     

  • PSE Index

    6,525.50
    -16.96 (-0.26%)
     

Silk Road Medical to Report Third Quarter 2021 Financial Results on November 9, 2021

Silk Road Medical
·1-min read

SUNNYVALE, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2021 after market close on Tuesday, November 9, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (844) 883-3861 for domestic callers or (574) 990-9820 for international callers, using conference ID: 3998078. A live and archived webcast of the event will be available at https://investors.silkroadmed.com/.

About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.

Investor Contact
Lynn Lewis or Marissa Bych
Gilmartin Group
investors@silkroadmed.com